الخلاصة

ABSTRACT Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed classes of drugs and their long-term regimens have been greatly shortened due to their gastrointestinal side effects. COX-2 plays a pivotal role throughout oncogenesis and here we exploit the rationale to explore the use of NSAID (Diclofenac and indomethacin) in combination with current anticancer drug (Gemcitabine) for the prevention and/or treatment of cancer. The study describes design and synthesis of mutual pro-drug of NSAID and gemicitabine, which is designated to generate the complementary pharmacological action as a single chemical entity with improved drug targeting. The synthesis is conferred by FT-IR, CHNS and physiochemical properties. The newly designed mutual pro-drug is expected to reduce the side effects of NSAIDs on the gastrointestinal (GI) tract with improvement of the oral bioavailability and targeting of gemcitabine.